Frans L. Stassen

Dr. Stassen is one of the co-founders of eXIthera Pharmaceuticals, Inc., a role in which he guided all areas of the discovery and development of Factor XIa inhibitors. Previously, Dr. Stassen served as the President and Chief Executive Officer of Daiamed and prior to that as the founding President and Chief Executive Officer of MyoGenics, Inc. Before joining the biotechnology industry, Dr. Stassen was Vice President of Research in Inflammation/Osteoarthritis, Molecular Biology, and Enzymology at Ciba-Geigy. He joined Ciba-Geigy from SmithKline in Philadelphia where he was Director of a cardiovascular drug discovery program. Dr. Stassen received his Ph.D. in Biochemistry and Cell Biology from the University of Nijmegen, The Netherlands.